一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Dapagliflozin: A Review in Type 2 Diabetes.

Published:1 July 2019 DOI: 10.1007/s40265-019-01148-3 PMID: 31236801
Sohita Dhillon

Abstract

Dapagliflozin (Forxiga?) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as add-on combination therapy (with other glucose-lowering agents, including insulin) for T2D when diet and exercise alone do not provide adequate glycaemic control. In numerous well-designed clinical studies and their extensions, dapagliflozin as monotherapy and combination therapy with other antihyperglycaemic agents provided effective glycaemic control and reduced bodyweight and blood pressure (BP) across a broad spectrum of patients. Dapagliflozin reduced the rate of cardiovascular (CV) death or hospitalization for heart failure (HHF), did not adversely affect major adverse CV events (MACE) and possibly reduced progression of renal disease relative to placebo in patients with established atherosclerotic CV disease (CVD) or multiple risk factors for CVD. Dapagliflozin was generally well tolerated, with a low risk of hypoglycaemia; diabetic ketoacidosis (DKA), although rare, and genital infections were more common with dapagliflozin than placebo. Given its antihyperglycaemic, cardioprotective and possibly renoprotective properties and generally favourable tolerability profile, dapagliflozin provides an important option for the management of a broad patient population, regardless of the history of CVD.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Dapagliflozin 461432-26-8 C21H25ClO6 828 suppliers $5.00-$1504.50
Dapagliflozin propanediol monohydrate 960404-48-2 C24H33ClO8 330 suppliers Inquiry

Similar articles

IF:13

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Drugs Greg L Plosker,etc Published: 3 December 2012
IF:13

Linagliptin: in type 2 diabetes mellitus.

Drugs Lesley J Scott,etc Published: 26 March 2011
IF:2.5

Efficacy of voglibose in type 2 diabetes.

Expert Opinion on Pharmacotherapy Kohei Kaku,etc Published: 1 June 2014
通山县| 普格县| 策勒县| 句容市| 玉屏| 五家渠市| 合江县| 北安市| 吉林省| 大悟县| 盱眙县| 仙游县| 富裕县| 冕宁县| 霍山县| 田东县| 勃利县| 旺苍县| 砚山县| 托克托县| 自贡市| 利川市| 登封市| 左贡县| 台安县| 加查县| 绥滨县| 龙山县| 博白县| 内黄县| 垦利县| 宝应县| 威海市| 彭山县| 永顺县| 郧西县| 扶绥县| 瑞金市| 利辛县| 无极县| 哈巴河县|